The use of nonsteroidal anti‐inflammatory drugs and the risk of Barrett’s oesophagus

Aliment Pharmacol Ther 2011; 34: 1235–1244

[1]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[2]  Peter J. Richardson,et al.  Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. , 2010, Gastroenterology.

[3]  H. Welch,et al.  Esophageal Adenocarcinoma Incidence: Are We Reaching the Peak? , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[4]  E. Kuipers,et al.  Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  H. McElroy,et al.  Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972–2005 , 2009, The Medical journal of Australia.

[6]  M. Winslet,et al.  Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort , 2009, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[7]  D. Whiteman,et al.  Current and past smoking significantly increase risk for Barrett's esophagus. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  C. Bain,et al.  Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus , 2008, Cancer Epidemiology Biomarkers & Prevention.

[9]  L. Bernstein,et al.  Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Adenocarcinomas in Los Angeles County , 2008, Cancer Epidemiology Biomarkers & Prevention.

[10]  M. Bronner,et al.  Central adiposity and risk of Barrett's esophagus. , 2007, Gastroenterology.

[11]  Kamran Ayub,et al.  NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma , 2007, PLoS medicine.

[12]  H. Comber,et al.  Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. , 2006, Cancer research.

[13]  J. Beebe-Dimmer,et al.  Chronic Inflammation: A Common and Important Factor in the Pathogenesis of Neoplasia , 2006, CA: a cancer journal for clinicians.

[14]  Carissa A. Sanchez,et al.  Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. , 2005, The Lancet. Oncology.

[15]  D. Whiteman,et al.  Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. , 2005, Journal of the American Academy of Dermatology.

[16]  D. Gotley,et al.  Interactions among Smoking, Obesity, and Symptoms of Acid Reflux in Barrett's Esophagus , 2005, Cancer Epidemiology Biomarkers & Prevention.

[17]  Hani Doss,et al.  Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). , 2005, Oncology reports.

[18]  R. López‐Ridaura,et al.  Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis , 2003, BMC Cancer.

[19]  J. Vane,et al.  The mechanism of action of aspirin. , 2003, Thrombosis research.

[20]  D. Vidaud,et al.  Cyclooxygenase‐2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma , 2003, Histopathology.

[21]  P. Mitchell,et al.  Systemic use of anti-inflammatory medications and age-related maculopathy: the Blue Mountains Eye Study , 2003, Ophthalmic epidemiology.

[22]  A. Tarnawski,et al.  NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action , 2002, American Journal of Gastroenterology.

[23]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[24]  S. Attwood,et al.  Cyclooxygenase-2 expression in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence , 2001, American Journal of Gastroenterology.

[25]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[26]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[27]  M. Omary,et al.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.

[28]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[29]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[30]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[31]  D. Watson,et al.  Prevalence of Symptoms and Use of Medication for Gastroesophageal Reflux in an Australian Community , 2008, World Journal of Surgery.

[32]  K. Kerlikowske,et al.  Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. , 2003, Gastroenterology.

[33]  R. Sampliner,et al.  Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus , 2002, American Journal of Gastroenterology.

[34]  P. Dítě,et al.  [Barrett's esophagus]. , 2000, Bratislavske lekarske listy.

[35]  K. Schrör,et al.  Cyclooxygenase-2 expression in human esophageal carcinoma. , 1999, Cancer research.

[36]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.